Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an announcement.
Vicore Pharma Holding AB announced its participation in the Oppenheimer Movers in Rare Disease Summit, where they will engage in a fireside chat and one-on-one meetings. This participation highlights Vicore’s ongoing efforts to position itself as a leader in the development of novel treatments for rare diseases, potentially enhancing its visibility and stakeholder engagement in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a new class of drugs with disease-modifying potential for respiratory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, currently in a Phase 2b trial and has received Orphan Drug and Fast Track designation from the FDA.
Average Trading Volume: 630,975
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.92B
See more insights into VICO stock on TipRanks’ Stock Analysis page.